Skip to main
IBIO
IBIO logo

iBio (IBIO) Stock Forecast & Price Target

iBio (IBIO) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

iBio Inc. is positioned favorably due to its innovative use of a proprietary AI-guided drug discovery platform, which enhances the development of targeted amylin receptor agonist antibodies, potentially increasing treatment durability while minimizing side effects. The company's preclinical studies demonstrated that its amylin receptor agonist antibody achieved a significant 60% reduction in food intake in mouse models, comparable to established treatments, indicating strong therapeutic potential. Additionally, the combination of iBio's lead drug candidate with semaglutide has shown enhanced weight loss and reduction in visceral fat, suggesting a promising non-appetite-based mechanism of action that could differentiate its product offerings in the competitive biotechnology landscape.

Bears say

The outlook on iBio's stock is negatively impacted by the potential for new treatment methods to render the company's therapies non-competitive or obsolete if these innovations succeed. Additionally, the reliance on the outcomes of ongoing and future clinical trials introduces significant uncertainty, as failure to meet clinical endpoints could lead to a decline in share value. Furthermore, potential disagreements with regulatory authorities regarding data interpretations from preclinical and clinical studies may pose additional risks to the company's viability and financial stability.

iBio (IBIO) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iBio (IBIO) Forecast

Analysts have given iBio (IBIO) a Buy based on their latest research and market trends.

According to 4 analysts, iBio (IBIO) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iBio (IBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.